Serum Prostate-Specific Antigen, Testosterone, and Creatinine Levels in Nigerian Men with Prostate Carcinoma versus Benign Prostatic Hyperplasia: A Comparative Cross-Sectional Study
Main Article Content
Abstract
Prostate carcinoma frequently presents at advanced stages in Nigeria and sub-Saharan Africa, where screening remains limited. The limited specificity of prostate-specific antigen (PSA) highlights the need to investigate complementary biomarkers. This study compared serum PSA, testosterone, and creatinine levels between men with histologically confirmed prostate carcinoma and those with benign prostatic hyperplasia (BPH) at a Nigerian tertiary hospital. A hospital-based analytical cross-sectional study enrolled 81 male patients over two years. Serum PSA and testosterone were measured using sandwich and competitive enzyme-linked immunosorbent assays, respectively, while creatinine was measured using the Jaffe kinetic method. Group comparisons employed independent-samples t-tests and one-way analysis of variance. Patients with carcinoma were significantly older than those with BPH (73.05 ± 7.68 vs. 65.63 ± 6.37 years; p < 0.001). The carcinoma group had higher mean serum PSA (40.43 ± 32.57 vs. 18.75 ± 6.75 ng/mL; p < 0.001) and creatinine (1.62 ± 0.86 vs. 1.09 ± 0.28 mg/dL; p < 0.001), but lower testosterone (2.77 ± 1.70 vs. 3.53 ± 1.26 nmol/L; p = 0.024). Prostate size did not differ significantly between groups (p = 0.401). These findings demonstrate differences in serum biochemical profiles between prostate carcinoma and BPH and support further investigation of a combined biomarker approach. Studies accounting for age differences and evaluating diagnostic performance are needed to establish whether testosterone and creatinine provide additional diagnostic value beyond PSA.
Citation Metrics:
Citation Metrics & Similar Scopus Articles
-
Sardar Khan S.K. (2027)MXene-based biosensors for biomedical diagnostics: From molecular recognition to wearable systemsAdvances in Biomarker Sciences and Technology, 9(1), 46-69
-
Grari O. (2027)Emerging biomarkers for human parasitic infections: Advances and future perspectivesAdvances in Biomarker Sciences and Technology, 9(1), 112-130
-
Cao Y. (2027)Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular CarcinomaNano Micro Letters, 19(1)
Article Details
References
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Adeloye, D., David, R. A., Aderemi, A. V., Iseolorunkanmi, A., Oyedokun, A., Iweala, E. E. J., Omoregbe, N., & Ayo, C. K. (2016). An estimate of the incidence of prostate cancer in Africa: A systematic review and meta-analysis. PLOS ONE, 11(4), Article e0153496. https://doi.org/10.1371/journal.pone.0153496
Rebbeck, T. R. (2018). Prostate cancer disparities by race and ethnicity: From nucleotide to neighborhood. Cold Spring Harbor Perspectives in Medicine, 8(9), Article a030387. https://doi.org/10.1101/cshperspect.a030387
Akinloye, O., Adaramoye, O. A., & Kareem, F. A. (2019). Serum prostate-specific antigen and biochemical changes in Nigerian men with prostate disorders. African Journal of Biomedical Research, 22(3), 245–252.
Jedy-Agba, E., Curado, M. P., Ogunbiyi, O., Oga, E., Fabowale, T., Igbinoba, F., Osubor, G., Otu, T., Kumai, H., Koechlin, A., Osinubi, P., Dakum, P., Blattner, W., & Adebamowo, C. A. (2012). Cancer incidence in Nigeria: A report from population-based cancer registries. Cancer Epidemiology, 36(5), e271–e278. https://doi.org/10.1016/j.canep.2012.04.007
Ogunbajo, M. A., Abiodun-Ojo, O. A., & Kareem, O. O. (2020). Clinicopathological characteristics and biochemical profile of prostate carcinoma at a tertiary hospital in Lagos, Nigeria. African Journal of Urology, 26(1), Article 34.
Obafunwa, J. O., Akang, E. E., & Ladipo, J. K. (1998). Cancer of the prostate in Ibadan, Nigeria: A ten-year retrospective study. African Journal of Medicine and Medical Sciences, 27(3–4), 185–188.
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Grummet, J., Henry, A. M., van der Kwast, T. H., Lam, T. B., Lardas, M., Liew, M., Mason, M. D., Moris, L., … Cornford, P. (2021). EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. European Urology, 79(2), 243–262. https://doi.org/10.1016/j.eururo.2020.09.042
Lilja, H., Ulmert, D., Björk, T., Becker, C., Serio, A. M., Nilsson, J.-Å., Abrahamsson, P.-A., Vickers, A. J., & Berglund, G. (2007). Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. Journal of Clinical Oncology, 25(4), 431–436. https://doi.org/10.1200/JCO.2006.06.9351
Loeb, S., Bjurlin, M. A., Nicholson, J., Tammela, T. L., Penson, D. F., Carter, H. B., Carroll, P., & Etzioni, R. (2014). Overdiagnosis and overtreatment of prostate cancer. European Urology, 65(6), 1046–1055. https://doi.org/10.1016/j.eururo.2013.12.062
Murtola, T. J., Kasurinen, T. V. J., Talala, K., et al. (2022). Prostate-specific antigen and prostate cancer: An updated review. European Urology Focus, 8(5), 1235–1243.
Nwofor, A. M. E., & Ugezu, A. I. (2004). Is serum prostate-specific antigen threshold of 4 ng/mL appropriate for all populations? Experience from south-east Nigeria. Nigerian Journal of Clinical Practice, 7(2), 57–60.
Muller, R. L., Gerber, L., Moreira, D. M., Andriole, G., Castro-Santamaria, R., & Freedland, S. J. (2012). Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. European Urology, 62(5), 757–764. https://doi.org/10.1016/j.eururo.2012.05.025
Keto, C. J., Aronson, W. J., Terris, M. K., et al. (2022). Serum testosterone levels and pathological features at radical prostatectomy. The Journal of Urology, 208(3), 580–586.
Platz, E. A., & Giovannucci, E. (2004). The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology, 92(4), 237–253. https://doi.org/10.1016/j.jsbmb.2004.10.002
Gu, X., Wu, J., Liu, X., Hong, Y., Wu, Y., & Tian, Y. (2022). Role of serum creatinine levels in prognostic risk stratification of prostate cancer patients. Medical Science Monitor, 28, Article e937100. https://doi.org/10.12659/MSM.937100
Mbata, G. C., Ukoli, C. O., Umeh, B. U., & Eze, G. U. (2019). Serum creatinine and electrolyte abnormalities in Nigerian patients with prostate cancer presenting with urinary obstruction. African Journal of Medicine and Medical Sciences, 48(1), 63–69.
Freedland, S. J., & Isaacs, W. B. (2005). Explaining racial differences in prostate cancer in the United States: Sociology or biology? The Prostate, 62(3), 243–252. https://doi.org/10.1002/pros.20052
Afolabi, A. O., Afolabi, O. A., & Adesunkanmi, A. R. (2021). Pattern of presentation and outcome of management of benign prostatic hyperplasia in a Nigerian tertiary institution. Pan African Medical Journal, 38, Article 124.
Lwanga, S. K., & Lemeshow, S. (1991). Sample size determination in health studies: A practical manual. World Health Organization. https://library.wpro.who.int/cgi-bin/koha/opac-detail.pl?biblionumber=17716
Vickers, A. J., Cronin, A. M., Bjork, T., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., Scardino, P. T., Ulmert, D., & Lilja, H. (2010). Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study. BMJ, 341, Article c4521. https://doi.org/10.1136/bmj.c4521
Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63–89. https://doi.org/10.14740/wjon1191
Adeniyi, A. A., Adeniyi, A. F., Oduniyi, A., & Akani, C. I. (2018). Age at presentation, clinical features and PSA values at diagnosis of prostate cancer in Nigerian men. African Journal of Urology, 24(1), 17–21.
Damber, J.-E., & Aus, G. (2008). Prostate cancer. The Lancet, 371(9625), 1710–1721. https://doi.org/10.1016/S0140-6736(08)60729-1
Eke, N., Ogo, C. N., & Nnoli, M. A. (2019). Pattern of metastatic spread in prostate cancer patients in Port Harcourt, Nigeria. Nigerian Journal of Clinical Practice, 22(3), 401–406.
Barry, M. J., Fowler, F. J., Jr., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., & Cockett, A. T. K. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Journal of Urology, 148(5, Part 1), 1549–1557. https://doi.org/10.1016/S0022-5347(17)36966-5
Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., De Santis, M., Gillessen, S., Grummet, J., Henry, A. M., van der Kwast, T. H., Lam, T. B., Mason, M. D., O’Hanlon, S., Oprea-Lager, D. E., Ploussard, G., van der Poel, H. G., Rouvière, O., Schoots, I. G., Tilki, D., & Wiegel, T. (2022). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. European Association of Urology.
Ngowi, B. N., Magoha, G. A. O., & Owuor, G. (2021). PSA patterns and clinical characteristics of prostate cancer in East African patients: A 10-year review. East African Medical Journal, 98(4), 3510–3518.
Owusu-Afriyie, O., Kyei, M. Y., Aboah, K., et al. (2019). PSA-to-creatinine ratio as a combined indicator of prostatic and renal pathology in Ghanaian men. Ghana Medical Journal, 53(2), 112–117.
Ajani, M. A., Oduwole, A. G., & Ogunleye, O. O. (2020). Serum testosterone and PSA levels in Nigerian men with histologically confirmed prostate cancer. Nigerian Journal of Clinical Practice, 23(5), 612–618.
Scardino, P. T. (1989). Early detection of prostate cancer. Urologic Clinics of North America, 16(4), 635–655. https://doi.org/10.1016/S0094-0143(21)01800-0
Article Sidebar
Page Numbers:
68-77
Digital Object ID:
Viewed: 22 times
Downloaded: 21 times
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:
Copyright :Authors retain copyright and grant the journal right of first publication.
Explore Our Journals
Find the journal that best fits your research. If this journal does not match your manuscript’s scope, explore our portfolio below to select a more suitable publication venue.